Chronic heart failure is one of the leading causes of mortality among patients with cardiovascular diseases. Current therapeutic methods for treating patients with chronic heart failure do not always provide a significant improvement in main intermediate and final outcomes. According to the neurohumoral theory of chronic heart failure development, an antagonism of the sympathoadrenal system with b-blockers is pathogenetically substantiated, and the drugs of this group are one of the first-line treatment for chronic heart failure. The selection of heart rate-reducing therapy in patients with chronic heart failure caused by ischemia, can often be difficult due to development of b-blockers side effects, b-blockers intolerance and/or due to the presence of contraindications at severe comorbid pathology. This article presents a clinical case of an effective administration of ivabradine, a drug of if-channel inhibitors group, in combination with b-blockers to a patient with chronic heart failure with a preserved ejection fraction.